Mandate

Vinge advises Platzer Fastigheter in conjunction with the acquisition of AB Volvos real estate portfolio in Gothenburg

February 08, 2017

The underlying real estate value amounts to approximately SEK 2.8 billion. The acquired portfolio consists of 338,000 square meters of rentable area as well as land located in Arendal, Torslanda and Säve. The ground area amounts to approximately 3.6 million square meters. The preliminary closing date is 15 December 2016. In order to finance part of the acquisition, Platzer intends to carry out a rights issue of approximately SEK 700 million. In connection with the acquisition, Platzer also intends to utilize bank financing of up to approximately SEK 1.7 billion. Vinge has advised Platzer in all parts of the transaction.

Vinge’s team consisted of partners Olof Jisland, Assur Badur, Charlotte Levin, Louise Brorsson Salomon, counsel Johan Cederblad, partner Robert Deli, associates Christian Lindhé, Anna-Maria Terzi, Anna Lonergan, Ludvig Frithiof, Kristoffer Larsson, Marith Welin-Berger, Emelie Parland and Frida Ställborn.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026